Galecto, Inc. (NASDAQ:GLTO – Get Free Report) fell 5.3% on Monday . The stock traded as low as $5.62 and last traded at $6.02. 48,435 shares traded hands during trading, an increase of 190% from the average session volume of 16,697 shares. The stock had previously closed at $6.36.
Wall Street Analyst Weigh In
Separately, Oppenheimer raised their price objective on Galecto from $9.00 to $10.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th.
View Our Latest Stock Report on GLTO
Galecto Stock Performance
Galecto Company Profile
Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Read More
- Five stocks we like better than Galecto
- The Role Economic Reports Play in a Successful Investment Strategy
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- What Are the U.K. Market Holidays? How to Invest and Trade
- Williams-Sonoma Stock: Buy It and Never Let It Go
- The Risks of Owning Bonds
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Galecto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galecto and related companies with MarketBeat.com's FREE daily email newsletter.
